Rigel Pharmaceuticals, Inc. (RIGL) News
Follow Rigel Pharmaceuticals, Inc. (RIGL) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 7 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
H
RIGL: VEPPANU launch and robust pipeline drive growth, with strong financials and raised guidance
A four-part growth strategy is driving expansion, highlighted by the VEPPANU acquisition and launch, which targets a billion-dollar breast cancer market. The pipeline, led by R289 in MDS, shows promising clinical results
EARNINGS | Sep 15, 2026, 03:00 PM UTC
L
RIGL: VEPPANU launch and robust pipeline position the business for accelerated growth and profitability
A four-pillar growth strategy is driving commercial expansion, highlighted by the VEPPANU acquisition and launch, which is expected to be a major growth driver in metastatic breast cancer. The pipeline, especially R289 i
MNA | Sep 15, 2026, 02:40 PM UTC
L
RIGL: VEPPANU's launch and pipeline progress drive growth, with strong financials and global expansion
The conference highlighted accelerated commercial growth, with VEPPANU's U.S. launch and global expansion, strong Q2 2026 financials, and a robust pipeline led by R289 in lower-risk MDS. Strategic licensing and disciplin
NEWS | Sep 15, 2026, 02:06 PM UTC
L
RIGL - Rigel to Participate in Upcoming September Investor Conferences
RIGL - Rigel to Participate in Upcoming September Investor Conferences
EQUITY | Sep 02, 2026, 12:05 PM UTC
L
Rigel PT raised to $49 from $40 by Piper Sandler
Piper Sandler raised its price target on Rigel (RIGL) to $49 from $40, according to TradeXchange Newsdesk.
EQUITY | Aug 17, 2026, 11:28 AM UTC
L
Rigel announces VEPPANU availability for ER+/HER2- ESR1-mutated breast cancer
Rigel (RIGL) says VEPPANU™ (vepdegestrant) is now available for patients with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer.
EQUITY | Aug 13, 2026, 12:06 PM UTC
L
RIGL RIGL - Rigel Reports Second Quarter 2026 Financial Results
RIGL RIGL - Rigel Reports Second Quarter 2026 Financial Results
EARNINGS | Aug 04, 2026, 08:01 PM UTC